Uses of histone acetyltransferase activators

Patent metadata

Field	Value
Publication number	US-9809532-B2
Application number	US-201214125214-A
Country	US
Kind code	B2
Filing date	Jun 11, 2012
Priority date	Jun 10, 2011
Publication date	Nov 7, 2017
Grant date	Nov 7, 2017

Abstract

The invention provides methods for enhancing histone acylation, learning, memory and/or cognition in subjects with compound (I) or compositions comprising compound (I), or a pharmaceutically acceptable salt thereof.

First claim

What is claimed:

1. A method for treating memory loss or a learning disability in a subject in need thereof, which comprises administering to the subject a therapeutically effective amount of compound (I):

or a pharmaceutically acceptable salt thereof, wherein the subject is not afflicted with a neurodegenerative condition or disease.

2. The method of claim 1 , wherein the neurodegenerative condition or disease is selected from the group consisting of adrenoleukodystrophy (ALD), alcoholism, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis (Lou Gehrig's Disease or ALS), ataxia telangiectasia, batten disease (Spielmeyer-Vogt-Sjogren-Batten disease), bovine spongiform encephalopathy (BSE), canavan disease, cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, familial fatal insomnia, frontotemporal lobar degeneration, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, lewy body dementia, neuroborreliosis, Machado-Joseph disease (spinocerebellar ataxia type 3), multiple system atrophy, multiple sclerosis, narcolepsy, Niemann Pick disease, Parkinson's disease, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, prion diseases, progressive supranuclear palsy, Rett's syndrome, tau-positive frontotemporal dementia, tau-negative frontotemporal dementia, Refsum's disease, sandhoff disease, Schilder's disease, subacute combined degeneration of spinal cord secondary to pernicious anaemia, spinocerebellar ataxia, spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, and toxic encephalopathy.

3. The method of claim 1 , wherein the neurodegenerative condition or disease is Alzheimer's.

4. The method of claim 1 , wherein the subject is a mammal.

5. The method of claim 1 , wherein the therapeutically effective amount is at least about 1 mg/kg body weight.

6. The method of claim 1 , wherein the therapeutically effective amount is at least 1 mg/kg body weight.

Assignees

• Francis Yitshak
• Arancio Ottavio
• Fa Mauro
• Univ Columbia

Inventors

• Francis Yitshak
• Arancio Ottavio
• Fa Mauro

Classifications

• A61P9/02

  Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P31/18

  for HIV · CPC title